Glycine, the smallest amino acid, confers neuroprotection against D-galactose-induced neurodegeneration and memory impairment by regulating c-Jun N-terminal kinase in the mouse brain

Rahat Ullah¹, Myeung Hoon Jo¹, Muhammad Riaz², Sayed Ibrar Alam¹, Kamran Saeed¹, Waqar Ali¹, Inayat Ur Rehman¹, Muhammad Ikram¹ and Myeong Ok Kim*¹

Abstract

Background: Glycine is the smallest nonessential amino acid and has previously unrecognized neurotherapeutic effects. In this study, we examined the mechanism underlying the neuroprotective effect of glycine (Gly) against neuroapoptosis, neuroinflammation, synaptic dysfunction, and memory impairment resulting from D-galactose-induced elevation of reactive oxygen species (ROS) during the onset of neurodegeneration in the brains of C57BL/6N mice.

Methods: After in vivo administration of D-galactose (D-gal; 100 mg/kg/day; intraperitoneally (i/p); for 60 days) alone or in combination with glycine (1 g/kg/day in saline solution; subcutaneously; for 60 days), all of the mice were sacrificed for further biochemical (ROS/lipid peroxidation (LPO) assay, Western blotting, and immunohistochemistry) analyses. An in vitro study, in which mouse hippocampal neuronal HT22 cells were treated with or without a JNK-specific inhibitor (SP600125), and molecular docking analysis were used to confirm the underlying molecular mechanism and explore the related signaling pathway prior to molecular and histological analyses.

(Continued on next page)
Results: Our findings indicated that glycine (an amino acid) inhibited D-gal-induced oxidative stress and significantly upregulated the expression and immunoreactivity of antioxidant proteins (Nrf2 and HO-1) that had been suppressed in the mouse brain. Both the in vitro and in vivo results indicated that D-gal induced oxidative stress-mediated neurodegeneration primarily by upregulating phospho-c-Jun N-terminal kinase (p-JNK) levels. However, D-gal + Gly cotreatment reversed the neurotoxic effects of D-gal by downregulating p-JNK levels, which had been elevated by D-gal. We also found that Gly reversed D-gal-induced neuroapoptosis by significantly reducing the protein expression levels of proapoptotic markers (Bax, cytochrome c, cleaved caspase-3, and cleaved PARP-1) and increasing the protein expression level of the antiapoptotic protein Bcl-2. Both the molecular docking approach and the in vitro study (in which the neuronal HT22 cells were treated with or without a p-JNK-specific inhibitor (SP600125)) further verified our in vivo findings that Gly bound to the p-JNK protein and inhibited its function and the JNK-mediated apoptotic pathway in the mouse brain and HT22 cells. Moreover, the addition of Gly alleviated D-gal-mediated neuroinflammation by inhibiting gliosis via attenuation of astrocytosis (GFAP) and microgliosis (Iba-1) in addition to reducing the protein expression levels of various inflammatory cytokines (IL-1β, TNFα). Finally, the addition of Gly reversed D-gal-induced synaptic dysfunction by upregulating the expression of memory-related presynaptic protein markers (synaptophysin (SYP), syntaxin (Syn), and a postsynaptic density protein (PSD95)) and markedly improved behavioral measures of cognitive deficits in D-gal-treated mice.

Conclusion: Our findings demonstrate that Gly-mediated deactivation of the JNK signaling pathway underlies the neuroprotective effect of Gly, which reverses D-gal-induced oxidative stress, apoptotic neurodegeneration, neuroinflammation, synaptic dysfunction, and memory impairment. Therefore, we suggest that Gly (an amino acid) is a safe and promising neurotherapeutic candidate that might be used for age-related neurodegenerative diseases.

Keywords: Glycine, D-galactose, Aging, Oxidative stress, c-Jun N-terminal kinase (JNK), Neuroapoptosis, Neuroinflammation, Neuroprotection

Background
Aging is a major factor in a number of chronic diseases, including cardiovascular disorder, diabetes mellitus, cancer, Parkinson’s disease (PD), and Alzheimer’s disease (AD) [1]. Previous research in the field of neuroscience has revealed that the human brain deteriorates with age. For decades, it has been known that central nervous system (CNS) disorders involve extensive neuronal death leading to brain dysfunction [2, 3]. Mitochondria are considered major intracellular sources of reactive oxygen species (ROS), which play vital roles in various age-associated neurological disorders [4]. Biomolecules generated as a result of excessive ROS and elevated oxidative stress (lipids, proteins, and DNA) disturb neuronal homeostasis, eventually leading to neuronal cell death [5].

D-galactose (D-gal) is a substance that occurs naturally in the body. Chronic systemic administration of D-gal in rats and mice is widely used to induce artificial senescence to model brain aging in animals and thereby assess the antiaging potential of pharmacological agents [1]. Accumulating evidences suggest that systemic chronic administration of D-gal accelerates cognitive and memory impairment in animals [6–9]. Normally, two different enzymes, namely galactose-1-phosphate uridyl transferase and D-galactokinase, are involved in the metabolism of D-gal in the body. However, at high concentrations, D-gal induces oxidative stress in the presence of galactose oxidase [1, 10]. Previous studies have reported that D-gal treatment upregulates oxidative stress and ROS levels, which causes activation of stress kinases, leading to neurodegeneration [5, 11]. c-Jun N-terminal kinase (JNK), also known as stress-activated kinase (JNK/SAPK), is a member of the complex superfamily of mitogen-activated protein kinases (MAPKs) and is activated in response to oxidative stress to mediate neuroapoptosis [12]. Numerous compelling lines of evidence strongly suggest that JNK functions as a proapoptotic kinase in neuronal apoptosis [11]. Studies have shown that JNK inhibition/knockdown reduces neuroapoptosis of hippocampal neurons [11, 13]. More recently, a study reported that active JNK enhances neuroinflammatory responses, synaptic loss, and cognitive deficits associated with neurodegeneration [14].

Glycine (Gly) is a dietary nonessential amino acid that is present as a metabolic intermediate in all organisms. Gly has been reported to be an antioxidant agent [15]. In addition, Gly treatment significantly reduces oxidative stress markers in the infarcted regions in the brain and causes significant normalization of the latency period of conditioned (behavioral) reflexes [16, 17]. Gly has not been reported to induce significant side effects in normal subjects (including rats and healthy volunteers) except for a mild sedative state. Another study reported that Gly exerts antistress and nootropic effects [18]. Also, glycine acts as a co-agonist for the channel opening of N-methyl-D-aspartate subtype of ionotropic glutamate...
receptors (NMDARs) [19–21] and therefore, facilitates neurotransmission [22]. Recently, Amin et al. demonstrated that Gly has a neuroprotective effect against ethanol-induced oxidative stress and neurodegeneration by stimulating the PI3K/Akt signaling pathway [15].

The aims of the present study were to investigate the mechanism underlying the neuroprotective effect of Gly against D-gal-induced neurodegeneration. Herein, our results showed that Gly cotreatment (1 g/kg/day) mitigates D-gal-induced oxidative stress, neuroapoptosis, neuroinflammation, synaptic dysfunction, memory impairment, and neurodegeneration in the brains of C57BL/6N mice. Importantly, both an in vitro study and molecular docking analysis supported our hypothesis that the neuroprotective effect of Gly might be due to JNK inhibition. This remarkable protection afforded by Gly, a neuroprotective amino acid, makes it a potentially safe, cost-effective, and easily administered agent.

**Experimental section: materials and methods**

**Chemicals**

D-galactose, glycine (Gly), JNK inhibitor (SP600125), and MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide), 2', 7-dichlorodihydrofluorescein diacetate (DCFH-DA) were purchased from Sigma Chemical Co (St. Louis, MO, USA).

**Experimental animals**

Male C57BL/6N mice (8 weeks; average body weight of 25–30 g) were purchased from Samtako Bio (Osan, S. Korea) and housed under a 12-h/12-h light/dark cycle in a temperature-controlled environment (20 ± 2 °C; humidity 50 ± 10%) in the animal care center of Gyeongsang National University, South Korea. The animals were provided ad libitum access to food and water. All the experimental animals were acclimatized for 1 week (7 days) in the animal care center. The experimental procedures were approved (approval ID: 125) by the animal ethics committee (IACUC) of the Division of Applied Life Sciences, Department of Biology at Gyeongsang National University, South Korea.

**Grouping of animals and drug treatment**

The experimental animals were equally divided into the following four groups (n = 16 mice/group).

1. Control (Cont. (C)) group: mice treated with normal saline (0.9%) (i.p) as a vehicle for 60 days.
2. D-galactose (D-gal) treatment group: mice treated with D-gal (100 mg/kg/day; i/p for 60 days).
3. D-gal + glycine (Gly) co-treatment group: mice treated with D-gal + Gly (1 g/kg/day in 0.9% normal saline solution) for 60 days.
4. Gly alone treatment group: mice treated with Gly for 60 days.

All the experimental procedures were carried out in accordance with the rules established by the local ethical committee for animals of the Department of Biology, Division of Applied Life Sciences of the Department of Biology in the Gyeongsang National University.

**Behavioral Analysis**

After administration of Gly and D-gal (D-gal; 100 mg/kg/day; i/p), we performed studies including the Morris water maze and Y-maze test.

**Morris water maze test**

The Morris water maze (MWM) test is a well-known and established task for evaluating memory functions; therefore, we performed the MWM as described previously [5]. The apparatus consisted of a circular water tank (diameter of 100 cm; height of 40 cm) filled with water (23 ± 1 °C) to a depth of 15.5 cm that was rendered opaque by the addition of white ink. A transparent escape platform (diameter of 4.5 cm, height of 14.5 cm) was hidden 1 cm below the surface of water in the center of one quadrant. Each mouse underwent four training trials/day for 4 consecutive days using the hidden platform. The escape latency (latency to find the submerged hidden platform) of each mouse in each trial was calculated. On day 5, we performed a probe test to evaluate memory consolidation. In the probe test, each mouse was allowed to freely swim for 60 s after the platform was removed. In the probe trial, the time spent in the target quadrant (where the platform has been located during hidden platform training), i.e., the time spent swimming in the target quadrant in an attempt to find the removed hidden platform, the time spent in the other three quadrants (left, right, and opposite), and the number of platform crossings were measured. The degree of memory consolidation was represented by the time spent in the target quadrant after learning. Visual/ video tracking software (SMART, Panlab Harvard Apparatus; Bioscience Company, Holliston, MA, USA) was used to record all data.

**Y-maze test**

For the Y-maze task, a Y-maze apparatus (height = 20 cm, length = 50 cm, and width = 10 cm at the bottom) was used [23]. The apparatus was constructed from black-painted wood and used for the evaluation of spatial working memory. Briefly, individual mice were placed in the middle of the maze and allowed to move freely (3- to 8-min sessions) for different intervals of time. The sequence of arm entries was digitally recorded. A spontaneous alternation was defined as successive entry into the three arms in overlapping triplet sets. The alteration percentage (%) was calculated as successive triplet sets/total number of arms entries × 2 × 100.
greater percentage (%) of spontaneous alteration behavior reflected better cognitive performance.

Collection of brain tissue and sample preparation
Briefly, after completion of drug treatment and behavior analyses, all the experimental mice ($n = 16$) were first anesthetized and then immediately sacrificed for immunofluorescence, morphological, and biochemical studies [24]. For morphological analysis, the experimental animals ($n = 8$ mice/group) were transcardially perfused with ice-cold PBS (0.01 M) followed by neutral-buffered paraformaldehyde (NBP; 4%) before the brains were postfixed in NBP (4%; 48–72 h). Next, the post-fixed brains of all the experimental mice were washed with 1% PBS (0.01 M) after removal of NBP and transferred into 20% sucrose solution (48 h) until they sank to the tube bottom. Finally, brains were frozen in O.C.T. compound (A.O. USA) before taking coronal cortical and hippocampal sections (14 μM) using microscopic slide via CM-3050CCryostat (Leica, Germany). The sections were thaw mounted on probe-on plus charged slides (Fisher, Rockford, IL, USA). Similarly, for biochemical or Western blotting ($n = 8$ mice/group), the brains were immediately removed, cortex and hippocampus tissue were carefully dissected, frozen on dry ice before stored at −80 °C. After homogenization in 0.2 M PBS with phosphatase inhibitor and protease inhibitor cocktail, these samples were centrifuged at 10,000 g at 4 °C for 30 min. The supernatants were collected and stored (−80 °C).

MTT and cell viability assays
The viability of treated mouse hippocampal neuronal HT22 cells was assessed by a colorimetric MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay according to the manufacturer’s instructions (Sigma Aldrich) to evaluate the effect of D-gal and/or Gly. The cells were cultured in 96-well plates (density = $1 \times 10^4$ cells/well; in Dulbecco’s modified Eagle’s medium (DMEM; 100 μL, Gibco, Life Technologies, USA)). After 24 h, the medium of the attached cells was refreshed with the indicated concentrations of d-gal (d-gal; 10, 50, 100, or 200 mM) and Gly (Gly; 10, 20, 30, and 40 μg/μL). The control cells were cultured in DMEM (0.01%) only. The cells were then further incubated for an additional 24 h. After being cultured for 24 h, the cells were incubated with 20 μL of MTT solution (5 mg/mL) for another 4 h at 37 °C. Subsequently, we removed the medium (50 μL) containing MTT solution from each well and added DMSO (100 μL/well). Finally, the 96-well plate was gently agitated on a shaker (10–20 min), and the absorbance was measured at 570 nm to evaluate the percentage of cell survival in all treatment groups using an ApoTox (Promega) instrument. The experiments were carried out in triplicate.

In vivo oxidative stress and lipid peroxidation assays
The reactive oxygen species (ROS) assay was performed according to a previously described procedure with some minor modifications [5]. This assay involved the conversion of 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) to 2′,7′-dichlorofluorescein (DCF) via oxidation. Briefly, a final concentration of 2.5 mg tissue/500 μL was obtained by diluting brain homogenates with ice-cold Lock’s buffer (1:20). Next, the reaction mixture was incubated with Lock’s buffer (1 mL, pH = 7.4), 0.2 mL of homogenate, and 10 mL of DCFH-DA (5 mM) at room temperature for 15 min, resulting in the formation of DCF (fluorescent product) from DCFH-DA. Using a spectrophuorometer, the converted fluorescent product, DCF, was measured (excitation/emission at 484/530 nm). To eliminate the background fluorescence (conversion of DCFH-DA in the absence of homogenate), blank samples were measured in parallel. ROS levels were measured as pmol DCF formed per minute per mg of protein.

Similarly, they lipid peroxidation LPO assay was performed to evaluate oxidative stress, as previously described [23]. The oxidative degradation of lipids can be quantified by measuring the free malondialdehyde (MDA) level. The level of MDA (a marker of LPO) was measured in the brain tissue homogenates using a lipid peroxidation (MDA) colorimetric/fluorometric assay kit (Bio Vision, USA, Cat # K739-100) according to the manufacturer’s protocol.

In vitro oxidative stress and lipid peroxidation assay
The in vitro ROS assay was conducted on mouse hippocampal neuronal HT22 cells as previously described [25]. Briefly, the cells were cultured in 96-well plates in DMEM (200 μL/well) supplemented with fetal bovine serum (FBS) (10%) and penicillin/streptomycin (1%). After 24 h of incubation in a humidified incubator (5% CO$_2$) at a temperature of 37 °C, the cells were treated with d-gal (100 mM), and d-gal (100 mM) with different concentrations of Gly (10, 20, 30, and 40 μg/μL) for 24 h. Subsequently, after treatment for 24 h, the cells were again exposed to DCFH-DA (50 μM/well) dissolved in DMSO/PBS and then incubated at 37 °C for 30 min. The relative absorbance of the plates (ROS-positive cells) was measured with the ApoToxGloTM assay (Promega Corp., Madison, WI, USA) at 484/530 nm. The results were expressed as pmol DCF formed/min/mg of protein in the cell lysate.

The in vitro LPO assay was performed to evaluate oxidative stress in HT22 cells as previously described [26]. A commercially available kit (Bio Vision Incorporated;
catalog # K739-100) was used for the LPO assay. Briefly, mouse hippocampal neuronal HT22 cells (2 × 10⁴/mL) were cultured in DMEM in 96-well plates and incubated in a humidified incubator (5% CO₂) at 37 °C. The cells were treated for 24 h by replacing the medium with fresh DMEM containing D-gal (100 mM D-gal) or D-gal + Gly (100 mM D-gal + 20 μg/μL Gly). Finally, LPO analysis was performed as described for earlier in vivo experiments.

Western blot and confocal microscopy analysis of in vitro cultures following drug treatment

HT-22 is an immortalized mouse hippocampal cell line (Millipore, US). HT22 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Thermo Fisher Scientific) supplemented with 10% FBS and 1% antibiotic/antimycotic in a humidified incubator containing 5% CO₂ at 37 °C [27]. After the cell reached almost 70–80% confluence, they were treated with D-gal (100 mM D-gal), D-gal + Gly (100 mM D-gal + 20 μg/μL Gly), D-gal + JNK-specific inhibitor (100 mM D-gal + 20 μg/μL SP600125), or D-gal + Gly + JNK-specific inhibitor (100 mM SP600125 + 20 μg/μL Gly + 20 μM SP600125) for 24 h.

For Western blot analysis, mouse hippocampal neuronal HT22 cells were washed, collected, and centrifuged in 0.01 M phosphate buffer saline (PBS; Amresco, Life Sciences, USA) to remove the supernatant. Then, PRO-PREP solution was used to dissolve the remaining pellets according to the manufacturer’s protocol (iNtRON Biotechnology, Burlington, NJ, USA) before sonication to obtain cell lysates. Finally, Western blot analysis was performed as described for the in vivo experiments.

Similarly, for immunofluorescence analysis, fixed mouse hippocampal neuronal HT22 cells were washed with 0.01 M phosphate buffer saline (PBS; Amresco, Life Sciences, USA). Next, proteinase K and blocking solution were used to stain the nuclei (7′,6-diamidino-2-phenylindole dihydrochloride) was used, and glass coverslips were mounted on the slides with mounting media. The staining patterns containing brain sections were covered with glass coverslips by using mounting media. The staining patterns were examined using a confocal laser scanning microscope (Flouview FV 1000, Olympus, Japan).

Antibodies

All antibodies used in the present study are summarized in Table 1.

Methodology of the molecular docking study

We performed a molecular docking study with MOE (Molecular Operating Environment) software to predict the binding mode of Gly in the binding pocket of the JNK protein (PDB ID 3VS6 chain A) [29]. The three-dimensional structure of Gly was generated with the builder tool of MOE. Next, the energy was minimized by using the default parameters (gradient: 0.1, Force Field: MMFF94X) after the generated structure was 3D protonated. For further evaluation of molecular docking, the
prepared compound was saved as a mdb (Molecular Data Base) file. The 3D structure of the target protein JNK was downloaded from a protein databank. The downloaded structure of the target protein JNK was opened in MOE, water molecules and the B chain were removed, and the JNK protein was 3D protonated. The energy of JNK protein was minimized for protein stability by using the default parameters in MOE. The default parameters, i.e., Placement: Triangle Matcher, Rescoring 1: London dG, Refinement: Force field, Rescoring 2: GBVI/WSA, were used for docking studies. Ten conformations were formed, and on the basis of docking score, the top ranked conformation was selected for further analysis.

**Fluoro-Jade B staining**

Fluoro-Jade B staining was performed as previously described [30]. Slides containing brain tissues were air-dried overnight. Following washes with PBS (2 × 10 min), the slides were immersed in 80% ethanol and 1% sodium hydroxide (NaOH) for 5 min. The slides were kept with ethanol (70% v/v) before being washed with distilled water for 2–3 min. Next, the slides were washed in distilled water for 2–3 min. Then, the slides were incubated in freshly prepared potassium permanganate (KMNO4, 0.06% w/v) for 10 min with gently shaking before being rinsed with distilled water. Next, the slides were dipped in Fluoro-Jade B (FJB) solution (0.01% v/v) containing 0.1% acetic acid and 0.01% Fluoro-Jade B for 20 min. After this, the slides were rinsed with distilled water, and DAPI was applied after they were dried (placing in an incubator for 10 min). The slides were mounted with glass coverslips using DPX nonfluorescent mounting medium. Representative images were captured using the FITC filter on a confocal laser scanning microscope (FV 1000, Olympus, Japan). The results were analyzed using the computer-based ImageJ program.

**Cresyl violet (Nissl) staining**

Nissl staining (cresyl violet) staining was performed to determine the degree of neuronal loss as previously described [31]. Tissue sections (14 μm thick) from the experimental mice were washed with PBS (0.01 M, 2 × 10 min). Cresyl violet solution was prepared by dissolving cresyl violet acetate (Sigma) in distilled water (containing a few drops of glacial acetic acid) at a concentration of 0.5% (w/v). The brain sections were stained with cresyl violet solution for approximately 10 min; rinsed with distilled water; dehydrated in 70% alcohol (for 5 min), 95% alcohol (for 5 min), and 100% alcohol (for 5 min); placed in xylene for 5 min; and covered with glass coverslips using nonfluorescent mounting medium, and images were taken with a fluorescent light microscope. The results were analyzed using computer-based ImageJ software, and GraphPad Prism 6 software was used to generate histograms.

**Data and statistical analyses**

In brief, ImageJ software was used to measure both the western blot data (density in arbitrary units (A.U.s) and the morphological data (integrated density in A.U.). The density values are expressed as the mean ± standard error mean (SEM) of triplicate wells (for in vitro experiments) and of 8 mice/group (for in vivo experiments) and are representative of three independent experiments. To generate graphs, we used GraphPad Prism 6 software.

| Antibody                        | Host  | Catalog | Application | Dilution | Manufacturer                                      |
|---------------------------------|-------|---------|-------------|----------|--------------------------------------------------|
| Anti-β-Actin antibody           | Mouse | sc-47778 | WB          | 1:1000   | Santa Cruz Biotechnology (Dallas, TX, USA)       |
| Anti-p-JNK antibody             | Mouse | sc-6254  | WB& IF      | 1:1000/1:100 | Santa Cruz Biotechnology (Dallas, TX, USA) |
| Anti-Bax antibody               | Mouse | sc-7480  | WB          | 1:1000   | Santa Cruz Biotechnology (Dallas, TX, USA)       |
| Anti-Bcl2 antibody              | Mouse | sc-7382  | WB          | 1:1000   | Santa Cruz Biotechnology (Dallas, TX, USA)       |
| Anti-PSD-95 antibody            | Mouse | sc-71933 | WB& IF      | 1:1000/1:100 | Santa Cruz Biotechnology (Dallas, TX, USA) |
| Anti-synaptophysin              | Rabbit| sc-7568  | WB          | 1:1000   | Santa Cruz Biotechnology (Dallas, TX, USA)       |
| Anti-syntaxin antibody          | Mouse | sc-12,736 | WB          | 1:1000   | Santa Cruz Biotechnology (Dallas, TX, USA)       |
| Anti-Iba-1 antibody             | Mouse | sc-32725 | WB          | 1:1000   | Santa Cruz Biotechnology (Dallas, TX, USA)       |
| Anti-GFAP antibody              | Mouse | sc-33673 | WB& IF      | 1:1000/1:100 | Santa Cruz Biotechnology (Dallas, TX, USA) |
| Anti-HO1 antibody               | Mouse | sc-136961| WB          | 1:1000/1:100 | Santa Cruz Biotechnology (Dallas, TX, USA) |
| Anti-Nrf2 antibody              | Mouse | sc-722   | WB& IF      | 1:1000/1:100 | Santa Cruz Biotechnology (Dallas, TX, USA) |
| Anti-IL-1β antibody             | Mouse | sc-7884  | WB& IF      | 1:1000/1:100 | Santa Cruz Biotechnology (Dallas, TX, USA) |
| Anti-cytochrome C               | Mouse | sc-13156 | WB& IF      | 1:1000/1:100 | Santa Cruz Biotechnology (Dallas, TX, USA) |
| Anti-PARP-1 Antibody            | Mouse | sc-56196 | WB          | 1:1000   | Santa Cruz Biotechnology (Dallas, TX, USA)       |
| TNF-α antibody                  | Mouse | sc-52746 | WB          | 1:1000   | Santa Cruz Biotechnology (Dallas, TX, USA)       |
Brains of normal saline-treated (control) mice. Glycine treatment attenuated D-galactose-induced cytotoxicity and ROS/LPO levels in HT-22 cells

The effect of D-gal and/or Gly on cell viability was evaluated by determining the viability of treated mouse hippocampal neuronal HT22 cells by the MTT assay according to the manufacturer’s instructions (Sigma Aldrich). To measure the effects of D-gal and Gly on cell viability, HT22 cells were treated with different concentrations of D-gal (10, 50, 100, or 200 mM) and Gly (10, 20, 30, or 40 μg/mL) for 24 h respectively. The MTT results indicated that D-gal treatment significantly reduced cell viability in a dose-dependent manner after 24 h (Fig. 1b). However, Gly was not toxic to the HT22 cells at any of the tested concentrations. No significant difference was found in viability between control cells and Gly-treated cells, indicating that Gly was not toxic to HT22 cells at all tested concentrations (Fig. 1c). Importantly, D-gal (100 mM) + Gly (10, 20, 30, 40 μg/mL) cotreatment significantly increased viability/cell survival and protected HT22 cells against D-gal-induced cytotoxicity (Fig. 1d).

Furthermore, to determine the antioxidant effect of Gly against D-gal-induced oxidative stress, we performed reactive oxygen species (ROS) and lipid peroxidation (LPO) assays in vitro. The in vitro assays indicated a significant increase in DCF (ROS levels) and LPO (MDA levels), suggesting that compared to control treatment, D-gal alone increased oxidative stress in HT22 cells (Fig. 1e, f). However, D-gal + Gly cotreatment significantly reduced the elevated ROS and MDA levels, as shown by the DCF and LPO assays (Fig. 1e, f). These findings indicate that Gly mitigates oxidative stress induced by D-gal in HT22 cells.

Glycine treatment reduced ROS/LPO levels and increased Nrf-2/HO-1 levels in the brains of D-galactose-treated mice

Previous studies have shown that D-gal is involved in oxidative stress-mediated neurodegeneration [1, 23]. To determine the antioxidant effect of Gly against D-gal-induced oxidative stress in the mouse brain, we performed reactive oxygen species (ROS) and lipid peroxidation (LPO) assays in vivo. Our results demonstrated that D-gal treatment considerably elevated ROS generation in the brains of D-gal-treated mice compared with the brains of normal saline-treated (control) mice. Conversely, Gly significantly reduced elevated ROS levels in both studied regions (the cortex and hippocampus) of the mouse brain. Similarly, Gly significantly reduced the increased LPO level induced by D-gal in the cortex and hippocampus of the mouse brain (Fig. 2a, b).

Furthermore, we checked the expression levels of antioxidant proteins, including nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1), by Western blotting to further confirm the antioxidant effect of Gly against D-gal in the mouse brain. Our immunoblot results revealed that the expression levels of Nrf-2 and HO-1 were substantially reduced in the brains of D-gal-treated mice compared to the brains of saline-treated mice. However, the expression level of the aforementioned antioxidant proteins was upregulated in the brains of D-gal + Gly-treated mice in comparison with the brains of D-gal-treated mice (Fig. 2c–e). Immunofluorescence analysis confirmed the Western blotting results for Nrf2; Nrf2 reactivity was significantly increased in both the cortex and hippocampus in the brains of D-gal + Gly-treated mice in comparison with D-gal-treated mice group (Fig. 2f, g). Additionally, both immunoblot and immunofluorescence analysis indicated that Gly was not toxic to the normal mice and showed no significant difference between normal saline-treated mice and Gly alone-treated mice (Fig. 2). Taken together, these findings indicate that through its antioxidant activities, Gly reverses D-gal-induced oxidative stress in the mouse brain.

Glycine treatment inhibited protein activation of p-JNK and apoptotic neurodegeneration mediated by D-galactose-induced oxidative stress in the mouse brain

Studies have reported that D-gal-mediated elevations of p-JNK initiates the mitochondrial apoptotic pathway, leading to neurodegeneration [32–35]. Therefore, consistent with these reports, we analyzed the effect of Gly against protein activation of p-JNK and its downstream neuroapoptotic markers mediated by D-gal-induced oxidative stress in the mouse brain. Our immunoblot results indicated that compared to saline treatment, D-gal treatment significantly increased the expression of p-JNK in both the cortex and hippocampus of the mouse brain. However, compared with D-gal alone, D-gal + Gly cotreatment markedly reduced the elevated expression of p-JNK (Fig. 3a). Additionally, immunoblot analysis showed that Gly alone treatment was not toxic to normal mice and revealed no significant difference between the brains of normal saline-treated (control) mice and those of Gly alone-treated mice. Similarly, early studies reported that activation of p-JNK by chronic treatment with D-gal has a direct impact on cytochrome C (Cyt C) release, which further activates caspases to mediate neuroapoptosis and
Therefore, to determine whether Gly reverses D-gal-induced neuronal apoptosis, we performed western blotting to examine the expression of various proapoptotic and antiapoptotic markers. Consistently, our results indicated that D-gal treatment significantly upregulated the protein expression level of cleaved caspase-3, cytochrome c (Cytc), and poly (ADP-ribose) polymerase 1 (PARP-1) while markedly downregulating the protein expression level of B cell lymphoma 2 (Bcl-2) in both the cortex and hippocampal of the brains of D-gal-treated mice. Conversely, D-gal + Gly cotreatment significantly reduced the elevated expression levels of cleaved caspase-3, Cyt C, and PARP-1 while upregulating the protein expression level of Bcl-2 in both indicated regions of the mouse brain (Fig. 3a).

Additionally, our immunofluorescence analysis also indicated significantly higher expression of p-JNK (in the cortex and hippocampus) and caspase-3 (in the hippocampus) in the brains of D-gal-treated mice than those of normal saline-treated (control) mice. However, D-gal + Gly cotreatment significantly reversed the increase in immunofluorescence reactivity of p-JNK and caspase-3 in both indicated regions of the mouse brain (Fig. 3b).

Furthermore, FJB and Nissl staining indicated that D-gal + Gly cotreatment reversed the effects of D-gal by significantly reducing the number of FJB-positive (+:ve) neuronal cells (in the cortex and hippocampus) and increasing the number of surviving neurons (in the cortex, DG, CA-1, and CA-3 regions of the hippocampus) in comparison with those in the brains of D-gal-treated mice (Fig. 3c, d). Taken together, these results indicate that Gly is effective in preventing protein activation of p-
Fig. 2 (See legend on next page.)
JNK and its downstream neuroapoptotic markers mediated by D-gal-induced oxidative stress in the mouse brain.

**Glycine treatment ameliorated D-galactose-mediated neuroinflammation and glial cell activation in the brains of D-galactose-treated mice**

Accumulating evidence suggests that D-gal-induced p-JNK activation results in the activation and accumulation of various inflammatory mediators [1, 37]. Therefore, we detected various inflammatory mediators, including interleukin 1 beta (IL-1β), by Western blotting and immunofluorescence analysis. We found significantly higher protein expression of TNF-α and IL-1β in the hippocampi of D-gal-treated mice than in the hippocampi of saline-treated (control) mice through Western blot analysis. However, D-gal + Gly cotreatment reversed the effect of D-gal and compared to D-gal alone, significantly reduced the increased expression of IL-1β and TNF-α in the hippocampus (Fig. 4a). Additionally, IL-1β immunofluorescence reactivity was significantly increased in both the cortex and hippocampus in the brains of D-gal alone-treated mice compared to those of saline-treated (control) mice. Interestingly, compared to D-gal alone, D-gal + Gly cotreatment significantly reduced the immunofluorescence reactivity of IL-1β in both the cortex and hippocampus (Fig. 4b, c).

Accumulative evidence has shown that astrocytosis and microgliosis increase with age and are higher in mouse model of D-gal-induced aging compared to control mice [5, 38]. To analyze the effect of Gly on the expression of GFAP and Iba-1, we performed immunoblotting and immunofluorescence. We found significant increases in the protein expression of GFAP and Iba-1 in the hippocampus in the brains of D-gal-treated mice compared to those of saline-treated (control) mice, as shown by Western blot analysis (Fig. 4a). However, compared to D-gal alone, D-gal + Gly cotreatment significantly reduced the elevated expression of GFAP and Iba-1 in the hippocampal region, indicating potent inhibition of microgliosis and astrocytosis (Fig. 4a). Likewise, our confocal microscopy results showed that GFAP immunofluorescence reactivity was significantly increased in the cortex and hippocampus (the CA1 region and dentate gyrus (DG)) in the brains of D-gal-treated mice compared to those of saline-treated (control) mice. Interestingly, compared with D-gal alone, D-gal + Gly cotreatment significantly reduced GFAP immunofluorescence in the cortex and hippocampus (the CA1 region and dentate gyrus (DG)) (Fig. 4d). Notably, both immunoblot and immunofluorescence analysis indicated that Gly was not toxic to the control mice and showed no significance difference between normal saline-treated mice and Gly alone-treated mice (Fig. 4). These findings indicate that Gly limits D-gal-induced p-JNK-mediated neuroinflammation in the hippocampus of the mouse brains.

**Glycine treatment improved synaptic dysfunction and enhanced learning, memory, and spontaneous alteration behavior in the brains of mice with D-galactose-induced memory impairment**

Several studies have reported altered expression of synaptic proteins or genes in D-gal-treated animals [23, 39]. To investigate the neurotoxic effect of D-gal and the neuroprotective effects of Gly on synaptic proteins, we performed Western blotting to analyze the expression of pre- and postsynaptic proteins. Our immunoblotting results revealed that memory-related presynaptic proteins, including synaptophysin (Syp), syntaxin (Syn), and a postsynaptic density protein (PSD95), were markedly decreased in the brains of D-gal-treated mice compared with those of saline-treated control mice. Interestingly, compared with D-gal alone, D-gal + Gly cotreatment significantly increased the expression levels of PSD95, SYP, and Syn in the hippocampus (Fig. 5a). Furthermore, our confocal microscopy results also suggested that PSD95 immunofluorescence reactivity was significantly decreased in the cortex and hippocampus in the brains of D-gal-treated mice compared with those of saline-treated (control) mice. However, compared with D-gal alone, D-gal + Gly cotreatment significantly increased the immunofluorescence reactivity of PSD95 in both regions (the cortex and hippocampus) (Fig. 5b). Additionally, both immunoblot and immunofluorescence analysis indicated that Gly was not toxic to the control mice and showed no
Fig. 3 (See legend on next page.)
Glycine treatment confers neuroprotection against D-galactose-induced neurotoxicity via downregulation of c-Jun N-terminal kinase in HT22 cells

After analyzing the aforementioned ant apoptotic and anti-inflammatory effects of Gly against D-gal in the mouse brain, we attempted to study the exact mechanism by which Gly confers neuroprotection. As reported in earlier studies, aberrant activation of the p-JNK protein in the hippocampus plays critical roles in mediating neuronal apoptosis [40]. Therefore, we hypothesized that the in vivo neuroprotective effect of Gly might be due to inhibition of D-gal-induced elevation of p-JNK levels. Thus, we examined the protein expression level of activated phosphorylated JNK (p-JNK) and its downstream signaling molecules in HT22 cells in vitro. Interestingly, consistent with our in vivo findings, our immunoblotting results revealed that compared with control treatment, D-gal alone significantly upregulated the protein expression levels of p-JNK and its downstream signaling molecules, including procaspase-3, Bax, and cleaved PARP-1, while significantly downregulating the protein expression level of an antiapoptotic protein (Bcl-2) in HT22 cells. However, compared to D-gal alone, D-gal + Gly cotreatment significantly downregulated the elevated protein expression levels of p-JNK, pro-caspase-3, Bax, and PARP-1 but upregulated the expression level of an antiapoptotic protein (Bcl-2) in neuronal HT22 cells (Fig. 6a). Additionally, the immunofluorescence reactivity of p-JNK and its downstream target caspase-3 was markedly decreased in Gly-treated HT22 cells compared to D-gal-treated HT22 cells.

To determine whether the neuroprotective effect of Gly against D-gal-induced neurotoxicity is JNK-dependent, we used a pharmacological JNK-specific inhibitor (SP600125) in HT22 cells. Interestingly, our in vitro immunoblotting and immunofluorescence results indicated that compared to other treatments, D-gal + Gly + SP600125 cotreatment markedly downregulated the protein expression and immunoreactivity of p-JNK levels and procaspase-3, which had been elevated by D-gal, reduced the protein expression of downstream signaling molecules of p-JNK (Bax and cleaved PARP-1), and upregulated the protein expression level of Bcl-2 in HT22 cells (Fig. 6a, b). In addition to these (wet laboratory) results, our molecular docking (dry laboratory) studies (shown in Fig. 7) revealed stable Gly-JNK protein interactions in which Gly interacted with multiple key residues of the target protein JNK to inhibit its function. Collectively, these results indicate that Gly reverses D-
Fig. 4 (See legend on next page.)
gal-induced elevation of p-JNK levels and downstream signaling in a JNK-dependent manner in HT22 cells in vitro.

**Molecular docking study: confirmation and interactions of glycine with the JNK protein**

We performed a molecular docking study to confirm the mechanism underlying the interaction between Gly and JNK. Among the different conformations, we observed the most favorable docking pose involves Gly inside the binding pocket of JNK in the proper orientation. The binding site comprises both hydrophobic and hydrophilic amino acids. The hydrophobic part resides include Ile70, Val78, Ala91, Ile124, Met146 and 149, Ala151, Val196, and Leu206, while the hydrophilic amino acids are Gly71, 73, Ser72, Gln75, Gly76, Lys93, Glu147, Asp150, Cys154, Glu155, 158, Ser193, Asn194, and Asn255. Analysis of the binding mode of the most favorable docking conformation revealed that the compound interacts well with hydrophilic amino acids (Gly73, Ser193, Asn194) over the binding cavity through OH, NH₂, and (C=O) groups by forming hydrogen bonds (Table 1). Figure 7 shows a 3-D depiction of the interactions associated with the favorable conformation. Thus, the binding ability of Gly was very strong in terms of binding affinity (−3.81 Kcal/mol), solvation energy (−18.63 Kcal/mol), and docking score (−15.5809 Kcal/mol). These values indicated good fitness of Gly in the binding pocket of the target protein and a stable Gly-JNK protein interaction. These theoretical results are consistent with the fact that Gly showed much stronger activity than other amino acids by engaging in multiple interactions with the key residues of the target protein JNK.

**Discussion**

Aging is one of the major factors in numerous chronic diseases, including diseases of the CNS [2, 3]. D-gal is a well-established agent for modeling brain aging and triggers neuronal death by upregulating JNK levels in animal models [5, 10, 23]. Herein, we identified the molecular mechanism underlying the neuroprotective effect of Gly (the smallest and simplest amino acid) against D-gal-mediated neurodegeneration and memory impairment. Our results indicated that D-gal induced oxidative stress-mediated neurodegeneration primarily by upregulating p-JNK levels. However, D-gal + Gly cotreatment reversed the neurotoxic effects of D-gal by downregulating D-gal-induced elevated p-JNK levels. Notably, both the molecular docking study and the in vitro study (in which neuronal HT22 cells were treated with or without a p-JNK-specific inhibitor (SP600125)) further support our in vivo findings that Gly binds to the p-JNK protein and inhibits its function. Therefore, we suggest that Gly-mediated deactivation of the JNK signaling pathway underlies the neuroprotective effect of Gly, which reverses D-gal-induced oxidative stress, apoptotic neurodegeneration, neuroinflammation, synaptic dysfunction, and memory impairment.

Oxidative stress has been suggested to be a common etiology of various CNS disorders [41]. Recent reports have demonstrated that chronic administration of D-gal (i/p for 8 weeks) increases oxidative stress and weakens antioxidant enzymes, which leads to aging and age-related memory impairment [23, 42]. Nrf2, a master endogenous antioxidant gene, is a stress-responsive transcription factor that is activated in response to oxidative stress and in turn activates other endogenous redox-regulated enzymes (HO-1), to counteract ROS-induced oxidative stress in various diseases, particularly neurodegenerative diseases [41]. In this regard, several studies have reported that D-gal-induced oxidative stress downregulates the protein expression of Nrf2 and HO-1 [43, 44]. Accordingly, our ROS and LPO assays indicated that Gly treatment significantly inhibited ROS and LPO levels in both D-gal-treated HT22 cells and the mouse brain. Moreover, we also found that Gly treatment reversed the D-gal effect by significantly increasing the protein expression levels of Nrf2 and HO-1. These findings indicate that Gly enhances the antioxidant response and limits D-gal-induced oxidative stress.
Fig. 5 (See legend on next page.)
The MAPK pathway, a conserved signal-transduction pathway, plays a vital role in modulating many physiological processes, including metabolism, gene expression, differentiation, mitosis, and apoptosis [45]. In mammalian cells, the JNK/SAPK (C-Jun N-terminal kinase/stress-activated protein kinase) family is a subfamily belonging to the MAPK superfamily [46, 47]. Recent studies have reported that JNK/SAPK are involved and activated in response to oxidative stress-induced insults [48] in numerous human diseases, including chronic inflammation, birth defects, cancer, ischemia/reperfusion injury, and neurodegeneration, particularly Parkinson’s disease and Alzheimer’s disease [49]. Several other studies have shown that oxidative stress elevates p-JNK levels in a model of d-gal-induced aging [1, 50]. Similarly, other studies have shown that JNK can function as a proapoptotic kinase that can induce neuroapoptosis, leading to cell death [11]. Others have reported that elevated p-JNK levels stimulate Cyt C/Caspase activation, leading to activation of the apoptotic signaling pathway [1]. The cytosolic release of cytochrome-C (Cyt C) stimulates the apoptotic protease cascade, which activates caspase-3 and thereby causes neuronal cell death [34]. Furthermore, poly (ADP-ribose) polymerase 1 (PARP-1) activation in response to elevated p-JNK levels is another hallmark of neuronal apoptosis [51]. Conversely, targeting p-JNK with a small-molecule peptide and specific JNK inhibitor (SP600125) alleviates JNK-mediated neuroapoptosis and neurodegeneration [49, 52]. Similarly, knockdown of JNK prevents apoptosis, whereas overexpression of JNK results in apoptosis in cultured sympathetic neurons [11, 53]. Accordingly, our in vitro and in vivo immunoblot results indicated that Gly treatment significantly downregulated the elevated protein expression level of p-JNK and its downstream apoptotic markers, including pro-caspase-3, Bax, and PARP-1, whereas it significantly upregulated the protein expression level of Bcl-2. In addition, the activated p-JNK and caspase-3 immunofluorescence and the FJB and Nissl staining indicated that Gly prevented apoptosis and neurodegeneration in the d-Gal-treated mouse brain. Importantly, we also elucidated the underlying mechanism by demonstrating that Gly prevented D-Gal-induced neurotoxicity in vitro in HT22 cells in a JNK-dependent manner because when JNK was inhibited with a specific inhibitor (SP600125) the D-gal-induced activation of the JNK-dependent apoptotic pathway was significantly reversed. Moreover, to further confirm these results, we performed a molecular docking (dry laboratory) study, which supported our findings that Gly forms a stable interaction with the JNK protein to inhibit its function. In addition to this, others reported that Gly act as co-agonist via N-methyl-D-aspartate receptor (NMDAR) to confer neuroprotection [54, 55]. Therefore, our findings indicate an additional/alternative neuroprotective mechanism of Gly against D-gal-induced apoptosis via suppression of the JNK-mediated apoptotic pathway.

Other studies have suggested that JNK, in addition to playing a critical role in mediating apoptotic signaling [56], is an important mediator of microglial activation [57] and neuroinflammation [58]. Chronic neuroinflammation is a potential risk factor for a broad range of age-associated diseases [59]. Additionally, the complex interactions between glial cells (microglia and astrocytes) are involved in acceleration of the neuroinflammatory response in neurodegenerative disorders [60]. Glial fibrillary acidic protein (GFAP) and ionized calcium-binding adaptor molecule (Iba-1) are specific markers of the activation of astrocytes and microglia, respectively [50]. Several lines of evidence have reported that D-gal treatment induces activation of Iba-1 and GFAP in a mouse model of D-gal-induced aging [5, 50], in which neuroinflammation is triggered by the release of various proinflammatory mediators (TNF-α and IL-1β) from glial cells [1, 61]. Similarly, we previously reported that D-gal leads to p-JNK overexpression in association with activation and accumulation of numerous inflammatory mediators [1]. Here, we found a marked increase in the levels of TNF-α and IL-1β in the hippocampal region in the brains of D-Gal-treated mice compared to those of saline-treated mice, which was significantly reversed by D-gal + Gly cotreatment. In addition, we found that compared to D-
Fig. 6 (See legend on next page.)

(a) Western blotting for p-JNK, JNK, Pro-caspase-3, Bax, Bcl-2, and PARP-1 in HT-22 cells treated with D-Gal, Gly, D-Gal + Gly, and D-Gal + Gly + SP600125.

(b) Immunofluorescence images showing DAPI, p-JNK, and PARP/p-JNK merged in HT-22 cells under different conditions.

(c) Immunofluorescence images showing DAPI, Casp-3, and DAPI/Casp-3 merged in HT-22 cells under different conditions.

Legend: a, b, c, d represent different treatments as follows:
- a: Control
- b: D-Gal
- c: D-Gal + Gly
- d: D-Gal + Gly + SP600125
Glycine alone, cotreatment with Gly and D-Gal markedly reduced the protein expression and immunofluorescence reactivity of GFAP and Iba-1 in the cortex and hippocampus. These findings indicate that Gly treatment is effective against D-gal-induced neuroinflammation via inhibition of JNK-mediated activation of glial cells and neuroinflammatory mediators.

Early studies linked oxidative stress and abnormal activation of the JNK signaling pathway with age-associated learning and memory deficits [62, 63]. Another study reported that brain functions largely depend on regulation of synaptic plasticity by synaptic proteins [39]. Importantly, D-gal treatment induced synaptic and memory impairment by downregulating memory-associated pre- and postsynaptic protein levels in the aging mouse brain [39, 64, 65]. Correspondingly, our results showed that D-gal treatment reduced the
expression levels of PSD95, SYP and Syn, whereas
cotreatment with Gly reversed this effect by signifi-
cantly alleviating the D-gal-induced decreased in these
memory-associated synaptic markers in the mouse
hippocampus. Similarly, in the MWM test, we found
that Gly treatment reduced the escape latency and in-
creased the number of platform crossings and the
amount of time spent by the mice in the target quad-
rant. Additionally, we found an increase in the per-
centage (%) of spontaneous alterations in the Y-maze
task. Taken together, these findings indicate that Gly
cotreatment improves behavior and memory by reduc-
ing D-gal-induced synaptic protein loss and spatial
learning/cognitive impairment. Based on these find-
ing, we suggest that Gly treatment is effective against
D-gal-induced cognitive impairment by reversing JNK-
mediated synaptic dysfunction and memory
impairment.

Conclusion
In conclusion, we demonstrate that treatment with Gly
(the smallest and simplest amino acid) efficiently abro-
gates D-gal-induced oxidative stress-mediated c-Jun N-
terminal kinase (JNK) activation, neuroapoptosis,
neuroinflammation, synaptic dysfunction, and memory
impairment in the brains of D-gal-treated mice (Fig. 8).
Based on both molecular docking analysis and an in vitro
study, we hypothesize that Gly, in addition to other well-
known effects via NMDR receptor, our approach provides
an additional/alternative neuroprotective mechanism of
Gly against D-gal-induced neurotoxicity, possibly through
inhibition of JNK protein function (binding ability + stable
Gly-JNK protein interactions). Future detailed studies
assessing the therapeutic efficacy and precise mechanisms
of Gly are encouraged to provide evidence for this amino
acid as an innovative therapeutic candidate for various
neurodegenerative disorders.

Fig. 8 Suggested graphical representation of possible glycine neuroprotective mechanism against D-gal-induced neurotoxicity. Glycine (amino acid) via inhibition of c-Jun N-Terminal kinase reduced D-gal-induced oxidative stress (ROS), neuroapoptosis, neuroinflammation, synaptic dysfunction, memory impairment, and neurodegeneration induced by D-galactose in C57BL/6N mice
Abbreviations
CNS: Central nervous system; jNK: c-Jun N-terminal kinase; MAPKs: Mitogen-activated protein kinase; TBST: Tris-buffered saline with Tween; PD: Parkinson’s disease; AD: Alzheimer’s disease; TNF: Tissue necrosis factor; PBS: Phosphate buffer saline; SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis; DAPI: 4'6-Diamidino-2-phenylindole; TRIT C: Tetramethylrhodamine isothiocyanate; FITC: Fluorescein isothiocyanate; Iba-1: Ionized calcium binding adapter molecule 1; GFAP: Glial fibrillary acidic protein

Acknowledgements
Not applicable.

Authors’ contributions
RU designed the study and wrote the manuscript. MJH conducted experiments and provided the experimental reagents. MR helped in molecular docking study. SAA conducted experiments and revised and edited the manuscript. KS reviewed, edited, and prepared the revised version of the manuscript. WA and IUR conducted the behavioral studies. MI performed statistical analysis. MOK supervised, organized, and reviewed approved the final version of the manuscript. All authors read and approved the final manuscript.

Funding
This research was supported by the Neurological Disorder Research Program of the National Research Foundation (NRF) funded by the Korean Government (MSIT) (2020M3E5D908066).

Availability of data and materials
The authors hereby declares that the generated datasets in this study will be presented upon request from the corresponding author.

Ethics approval
All the experiments with animal and other experimental protocols and procedures were approved (Approval ID: 125) by the Ethics Review Committee of the Gyeongsang National University, Republic of Korea.

Consent for publication
Not applicable.

Competing interests
The authors declare no conflict of interest.

Author details
1Division of Life Sciences and Applied Life Science (BK 21plus), College of Natural Science, Gyeongsang National University, Jinju 52828, Republic of Korea. 2Department of Biochemistry, Abdul Wali Khan University Mardan, Mardan, Khyber Pakhtunkhwa 23200, Pakistan.

References
1. Ullah F, Ali T, Ullah N, Kim MO. Caffeine prevents D-galactose-induced cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain. Neurochem Int. 2015;90:14–24.
2. Morrison JH, Hof PP. Life and death of neurons in the aging brain. Science. 1997;278:412–9.
3. Raz N, Ghisletta P, Rodrigue KM, Kennedy KM, Lindenberger U. Trajectories of cognitive deficits, oxidative stress, neuroinflammation and neurodegeneration via RAGE/NF-kappaB signaling pathway activation. Cereb Cortex. 2010;20:2540–8.
4. Fiskum G, Rosenthal RE, Vereczki V, Martin E, Hoffman GE, Chinopoulos C, Kowaltowski A. Protection against ischemic brain injury by inhibition of mitochondrial oxidative stress. J Bioenerg Biomembr. 2004;36:347–52.
5. Ali T, Badshah H, Kim TH, Kim MO. Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF-KB/JNK signaling pathway in aging mouse model. J Physiol. 2015;58:71–85.
6. Zhang XL, Jiang B, Li ZB, Hao S, An LJ. Catalpol ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by D-galactose. Pharmacol Biochem Behav. 2007;88:64–72.
7. Cui X, Zuo P, Zhang Q, Li X, Hu Y, Long J, Packer L, Liu J. Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid. J Neurosci Res. 2006;84:467–54.
8. Kumar A, Prakash A, Dogra S. Centella asiatica attenuates D-galactose-induced cognitive impairment, oxidative and mitochondrial dysfunction in mice. Int J Alzheimers Dis. 2011;2011:347569.
9. Kumar A, Prakash A, Dogra S. Centella asiatica attenuates D-galactose-induced cognitive impairment, oxidative and mitochondrial dysfunction in mice. Int J Alzheimers Dis. 2011;2011:19.
10. Lu J, Wu DM, Zheng YL, Hu B, Zhang ZF, Ye Q, Liu CM, Shan Q, Wang YJ. Ursolic acid attenuates D-galactose-induced inflammatory response in mouse prefrontal cortex through inhibiting AGEs/RAGE/NF-kappaB pathway activation. Brain Res. 2012;1549:20–8.
11. Li J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell. 2005;15:36–42.
12. Maddux BA, Grodsky GM, Goldfine ID, Evans JL. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599–622.
13. Koch P, Gehringier M, Lafer SA. Inhibitors of c-Jun N-terminal kinase: an update. J Med Chem. 2015;58:72–95.
14. Zhou Q, Wang M, Du Y, Zhang W, Bai M, Zhang Z, Li Z, Mao J. Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/P51dE9 mice. Ann Neurol. 2015;77:837–54.
15. Amin FU, Shah SA, Kim MO. Glycine inhibits ethanol-induced oxidative stress, neuroinflammation and apoptotic neurodegeneration in postnatal rat brain. Neurochem Int. 2016;96:1–12.
16. Castillo J, Davalos A, Naviero J, Noya M. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke. 1996;27:1060–5.
17. Gusev EL, Skvortsova VI, Dambinova SA, Raevsky KS, Alekseev AA, Bashkatova VG, Kovalenko AV, Kudrin VS, Yakovleva EV. Neuroprotective effects of glycine for therapy of acute ischaemic stroke. Cerebrovasc Dis. 2000;10:49–60.
18. IA k. Medicinal preparation of antistress, stress-protective and nootropic effect. United States: 1988.
19. Leson PD, Ivenen LL. The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential. J Med Chem. American Chemical Society (ACS); 1993;37:4053–67. https://pubs.acs.org/doi/10.1021/ jm00050a001.
20. Johnson, J. Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 1987;325:529–31.
21. Bannai M, Kawai N. New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep. J Pharmacol Sci. 2012;118:145–8.
22. Shoham S, Javitt DC, Heresco-Levy U. Chronic high-dose glycine nutrition: effects on rat brain cell morphology. Biol Psychiatry. 2001;49:876–85.
23. Rehman SU, Shah SA, Ali T, Chung JL, Kim MO. Anthocyanins reversed D-galactose-induced oxidative stress and neuroinflammation mediated cognitive impairment in adult rats. Mol Neurobiol. 2017;54:255–71.
24. Shah SA, Yoon GH, Kim MO. Protection of the developing brain with anthocyanins against ethanol-induced oxidative stress and neurodegeneration. Mol Neurobiol. 2015;51:1278–91.
25. Muhammad T, Ikrarm M, Ullah R, Rehman SU, Kim MO. Hesperetin, a citrus flavonoid, attenuates LPS-induced neuroinflammation, apoptosis and memory impairments by modulating TL/4/NF-kappaB signaling. Nutrients. 2019;11(3):648. https://doi.org/10.3390/nu11030648.
26. Khan MS, Ali T, Kim MW, Jo MH, Chung JL, Kim MO. Anthocyanins improve hippocampus-dependent memory function and prevent neurodegeneration via jNK/Akt/GSK3beta signaling in LPS-treated adult mice. Mol Neurobiol. 2019;56:671–87.
27. Khan M, Rutton BP, Kim MO. MST1 regulates neuronal cell death via jNK/Casp3 signaling pathway in HDL mouse brain and HT22 cells. Int J Mol Sci. 2019;20(10): 2504. https://doi.org/10.3390/ijms20102504.
28. Shah SA, Lee HY, Bressan RA, Yun DJ, Kim MO. Novel osmotin attenuates glutamate-induced synaptic dysfunction and neurodegeneration via the JNK/PI3K/Akt pathway in postnatal rat brain. Cell Death Dis. 2014;5:e1026.
29. Molecular Operating Environment (MOE), 2016.08; Chemical computing group Inc., 1010 Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7., 2016.
30. Badshah H, Ali T, Kim MO. Osmotin attenuates LPS-induced neuroinflammation and memory impairments via the TL4/NF-kappaB signaling pathway. Sci Rep. 2016;6:24493.
31. Badshah H, Kim TH, Kim MJ, Ahmad A, Ali T, Yoon GH, Naseer MI, Kim MO. Apomorphine attenuates ethanol-induced neurodegeneration in the adult rat cortex. Neurochem Int. 2014;74:8–15.

32. Cui X, Zuo P, Zhang Q, Li X, Hu Y, Long J, Packer L, Liu J. Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid. J Neurosci Res. 2006;83:1584–90.

33. Lu J, Zheng YL, Wu DM, Luo L, Sun DX, Shan Q. Usoil acid ameliorates cognition deficits and attenuates oxidative damage in the brain of senescent mice induced by D-galactose. Biochem Pharmacol. 2007;74:1078–90.

34. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and cATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479–89.

35. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312–6.

36. Lu J, Dm W, Yl Z, Hu B, Zf Y. Purple sweet potato color alleviates D-galactose-induced brain aging in old mice by promoting survival of neurons via PKR pathway and inhibiting cytochrome c-mediated apoptosis. Brain Pathol. 2010;20:598–612.

37. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov. 2003;2:554–65.

38. Salminnen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Inflammation in neurodegenerative diseases. J Neuropathol Exp Neurol. 2011;70:315–31.

39. 80. Liu R, Liu IY, Bi X, Thompson RF, Doctrow SR, Malfroy B, Baudry M. Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc Natl Acad Sci U S A. 2003;100:8526–31.

40. Tang Y, Xu A, Shao S, Zhou Y, Xiong B, Li Z. Electroacupuncture ameliorates cognitive impairment by inhibiting the JNK signaling pathway in a mouse model of Alzheimer’s disease. Front Aging Neurosci. 2020;12:23.

41. Wei H, Li L, Song Q, Ai H, Chou J, Li W. Behavioural study of the D-galactose induced aging model in C57BL/6J mice. Behav Brain Res. 2005;157:45–51.

42. Mehan S, Meena H, Sharma D, Sankhla R. JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer’s and various neurodegenerative abnormalities. J Mol Neurosci. 2011;43:376–90.

43. Parashar K, Irwin MH, Sellouk K, Pinkert CA. D-galactose effectiveness in modeling aging and therapeutic antioxidant treatment in mice. Rejuvenation Res. 2010;13:729–35.

44. Ramsey CP, Glass CA, Montgomery MB, Lindli KA, Riston GP, Chia LA, Hamilton RL, Chu CT, Jordan-Sciutto KL. Expression of Nrf2 in primary astrocytes. J Neuroinflammation. 2015;12:225.

45. Hu R, Chen J, Lujan B, Lei R, Zhang M, Wang Z, Liao M, Li Z, Wan Y, Liu F, et al. Glycine triggers a non-ionotropic activity of GluN2A-containing NMDA receptors to confer neuroprotection. Sci Rep. 2016;6:34459.

46. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene. 2008;27:6245–51.

47. Parashar K, Irwin MH, Sellouk K, Pinkert CA. D-galactose effectiveness in modeling aging and therapeutic antioxidant treatment in mice. Rejuvenation Res. 2010;13:729–35.

48. Mehan S, Meena H, Sharma D, Sankhla R. JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer’s and various neurodegenerative abnormalities. J Mol Neurosci. 2011;43:376–90.

49. Liu R, Liu IY, Bi X, Thompson RF, Doctrow SR, Malfroy B, Baudry M. Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc Natl Acad Sci U S A. 2003;100:8526–31.

50. Tang Y, Xu A, Shao S, Zhou Y, Xiong B, Li Z. Electroacupuncture ameliorates cognitive impairment by inhibiting the JNK signaling pathway in a mouse model of Alzheimer’s disease. Front Aging Neurosci. 2020;12:23.

51. Wei H, Li L, Song Q, Ai H, Chou J, Li W. Behavioural study of the D-galactose induced aging model in C57BL/6J mice. Behav Brain Res. 2005;157:45–51.

52. Shwe T, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. Role of D-galactose-induced brain aging and its potential used for therapeutic interventions. Exp Gerontol. 2018;101:13–36.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.